NCT04887935 is a Phase 1 clinical trial of Dapagliflozin in Prostate Cancer, sponsored by Washington University School of Medicine.

Who is sponsoring NCT04887935?

NCT04887935 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT04887935?

Interventions in NCT04887935: Dapagliflozin.

What condition does NCT04887935 study?

NCT04887935 studies Prostate Cancer, Cancer of Prostate.

Is NCT04887935 still recruiting?

NCT04887935 is currently recruiting now. Last updated 1 October 2025.

Last reviewed 2025-10-01 · How we verify

NCT04887935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Recruiting now Phase 1 Last updated 1 October 2025

What this trial tests

Phase 1 trial testing Dapagliflozin in Prostate Cancer in 24 participants. Currently enrolling.

Timeline

4 June 2024

Primary endpoint
31 August 2026

31 August 2026

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	4 June 2024
Primary completion	31 August 2026
Estimated completion	31 August 2026
Sites	1 location across United States

Drugs / interventions tested

Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Cancer of Prostate — all drugs for Cancer of Prostate →

Sponsor

Washington University School of Medicine

Who can join

18 and older, male only, with Prostate Cancer or Cancer of Prostate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious in resulting in tumor shrinkage on pre-operative imaging and will result in tumor necrosis at prostatectomy.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.
Pandey A, Alcaraz M, Saggese P, Soto A, et al · · 2025 · cited 21× · PMID 39941833 · DOI 10.3390/cancers17030466
The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data.
Zheng J, Lu J, Qi J, Yang Q, et al · · 2024 · cited 14× · PMID 39168098 · DOI 10.1016/j.xcrm.2024.101688
Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.
Camilli M, Viscovo M, Maggio L, Bonanni A, et al · · 2025 · cited 9× · PMID 38935171 · DOI 10.1007/s00395-024-01059-9
Solute Carrier transporters in tumor metabolism and immune modulation: implications for therapy.
Zhou J, Wen W, Xu Y, Yu J, et al · · 2026 · PMID 41832499 · DOI 10.1186/s12967-026-07918-4
SGLT2 Inhibitors in Combination Therapies for Tumors: A Novel Approach to Synergistic Treatment Strategies.
Su H, Li X, Wang S, Yang X, et al · · 2025 · PMID 41477177 · DOI 10.2147/dddt.s556231
Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate Cancer.
Perez Kerkvliet CJ, Leong JY, Thompson RAM, Zarrabi KK, et al · · 2025 · PMID 40647555 · DOI 10.3390/cancers17132258
Mendelian randomization revealing the protective effect of sodium-glucose cotransporter 2 inhibition on prostate cancer with verified evidence from electronic healthcare and biological data
Zheng J, Lu J, Qi J, Yang Q, et al · · 2023 · DOI 10.1101/2023.10.10.23296790

Verify or expand the search:

Other trials of Dapagliflozin

Trials testing the same drug.

NCT07491042 — Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. · NA · recruiting
NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07239011 — Dapagliflozin in Depression · Phase 1, PHASE2 · recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04887935 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 1 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04887935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing